LinK-MAndersonDPolandRE. Ethnic and cultural considerations in psychopharmacotherapy. Pp. 75–81. In: DunnerDL. ed. Current Psychiatric Therapy, 2nd ed.Philadelphia: W.B. Saunders Company, 1997.
2.
LinKPolandR.Ethnicity, Culture and Psychopharmacology. In: BloomFKupferD, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995;1907–1917.
3.
LinKPolandRNakasakiG.Psychopharmacology and psychobiology of ethnicity. Washington, DC: American Psychiatric Press. 1993.
4.
KalowW.Pharmacogenetics: its biological roots and medical challenge. Clinical Pharmacolology Therapy1993;54:235–241.
5.
FrackiewiczEJSramekJJHerreraJMKurtzNMCutlerNR. Ethnicity and antipsychotic response. Annalls of Pharmacotherapy1997;31(11):1360–1369.
6.
LinKPolandRLauIRubinR.Haloperidol and prolactin concentrations in Asians and Caucasians. J Clinical Psychopharmacololy1988;8:195–201.
7.
LinKPolandRNuccioILongitudinal assessment of Haloperidol dosage and serum levels and concentrations in Asian and Caucasianschizophrenic patients. American Journal of Psychiatry1989;146:1307–1311.
8.
AndersonKKappasA.Dietry regulation of cytochrome P450. Annual Review of Nutrition1991;11:141–167.
9.
MatsudaKTChoMCLinK-MSmithMWClozapine dosage, serum levels, efficacy, and side-effect profiles: A comparison of Korean-American and Caucasian patients. Psychopharmacology Bulletin1996;32(2):253–257.
10.
KleinmanA.Rethinking psychiatry. New York: The Free Press, 1988.
11.
SmithMLinKMendozaR.“Non-biological” issues affecting psychopharmacotherapy: Cultural considerations. In: LinKPolandRNakasakiG, eds. Psychopharmacology and psychobiology of ethnicity. Washington, DC: American Psychiatric Press, 1993.
12.
LeeS.Side effects of chronic lithium therapy in Hong Kong Chinese: an ethnopsychiatric perspective. Culture Medicine and Psychiatry1993;17:301–320.
13.
MinasILambertTKostovSBorangaG.Mental health services for NESB immigrants: Transforming policy into practice. Canberra: Australian Government Publishing Service, 1996.
14.
LambertT.Brief Observations on Research Methods in Clinical Trials. Australasian Psychiatry1997;5(2):66–69.
15.
KaySFizbeinAOplerL.The positve and negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13(2):261–276.
16.
LambertT.Interrater reliability and the PANSS: What does it tell us about efficacy in neuroleptic trials?European Neuropsychopharmacology1996;6 (Suppl 3):199–200.